BG Medicine has named Eric Bouvier as the company's new president and chief executive officer (CEO).
Since May 2011, Bouvier served at Leica Microsystems, a Danaher company, as the company’s president.
Eric served as corporate vice president and deputy CEO at bioMerieux, SA from October 2002 to April 2011, where he was responsible for the Immunoassay Business Unit (a $500 million business by sales) and Global Human Resources.
Eric also served as president and CEO at bioMerieux Inc, the company’s US subsidiary, and before that he held various marketing, sales management and sales positions with bioMerieux and other companies.
BG Medicine CEO and president Eric Bouvier said he look forward to advance their galectin-3 and AMIPredict diagnostic tests into major commercial successes by helping millions of patients around the world.
"We will now build on the company’s early successes to rapidly become a full-fledged commercial company," Bouvier said.
BG Medicine executive vice president CMO Pieter Muntendam said they developed galectin-3 and AMIPredict, which have the potential to transform detection and care for two important and common cardiovascular conditions.